Gyre Therapeutics (GYRE) Change in Receivables (2013 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Change in Receivables of -$8.6 million for Q1 2026, down 1287.4% year-over-year from $722000.0 in Q1 2025, and down 277.68% quarter-over-quarter from $4.8 million in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Change in Receivables (2013 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Change in Receivables for 11 consecutive years, with -$8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 1287.4% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 200.64% YoY), while the FY2025 annual figure was $10.8 million, up 105.55% from the prior year.
- Change in Receivables retreated to -$8.6 million in Q1 2026 per GYRE's latest filing, from $4.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $4.8 million in Q4 2025 and bottomed at -$8.6 million in Q1 2026.
- Historically, Change in Receivables has averaged -$583000.0 across 4 years, with a median of $79000.0 in 2022.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 321.03% — and 2026, when it sank 1287.4%.
- Gyre Therapeutics' Change in Receivables stood at -$564000.0 in 2022, then surged by 303.19% to $1.1 million in 2024, then soared by 321.03% to $4.8 million in 2025, then tumbled by 277.68% to -$8.6 million in 2026.
- Business Quant data shows GYRE's Change in Receivables at -$8.6 million in Q1 2026, $4.8 million in Q4 2025, and $722000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 4.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Mar 31, 2026 | -8.57 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 4.24 Mn |
| Mar 31, 2025 | 722,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Jun 30, 2022 | -564,000.00 |
| Mar 31, 2022 | -1.05 Mn |
| Dec 31, 2021 | 704,000.00 |
| Sep 30, 2021 | -857,000.00 |
| Jun 30, 2021 | 965,000.00 |
| Mar 31, 2021 | -2.31 Mn |
| Dec 31, 2020 | 1.76 Mn |
| Sep 30, 2020 | -433,000.00 |
| Jun 30, 2020 | 622,000.00 |
| Mar 31, 2020 | -13.63 Mn |
| Dec 31, 2017 | -27,000.00 |
| Sep 30, 2017 | -83,000.00 |
| Jun 30, 2017 | -93,000.00 |